SCHEMBL3545187

SCHEMBL3545187

O=C(O)CC1(c2[c]cccc2)CCCC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.46
TSHR P16473 1/20 0.38
LMNA P02545 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
EPHX2 P34913 1/20 0.36
DPP4 P27487 1/20 0.36
AKR1C1 Q04828 1/20 0.36
ALDH1A1 P00352 2/20 0.35
USP2 O75604 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP2C19 P33261 2/20 0.34
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3542554 0.98 HSD11B1 (0.49) HSD11B1TSHRLMNASMN1; SMN2L3MBTL1
SCHEMBL3545670 0.84 HSD11B1 (0.35) HSD11B1LMNASMN1; SMN2L3MBTL1NPSR1
SCHEMBL3548276 0.81 ALDH1A1 (0.36) LMNASMN1; SMN2L3MBTL1NPSR1ALDH1A1
SCHEMBL5311763 0.81 SLC6A3 (0.38) HSD11B1LMNAKMT2A
SCHEMBL3542654 0.80 GAA (0.45) TSHRSMN1; SMN2NPSR1ALDH1A1MEN1
SCHEMBL3545675 0.79 GAA (0.44) TSHRLMNASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL977926 0.75 HSD11B1 (0.69) HSD11B1TSHRLMNASMN1; SMN2L3MBTL1
SCHEMBL3549433 0.75 CETP (0.33) LMNAL3MBTL1ALDH1A1HSD17B10MEN1
SCHEMBL21899380 0.75 SLC6A4 (0.39) DPP4
SCHEMBL3543714 0.75 AKR1C1 (0.56) TSHRLMNASMN1; SMN2L3MBTL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US claimed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US claimed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US claimed
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 HSD11B1 117/4885TSHR 1451/4885LMNA 3296/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 HSD11B1 126/4885TSHR 1169/4885LMNA 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.